Statins, Glycemia, and Diabetes Mellitus: Another Point of View

Current Atherosclerosis Reports

Volumn 16, Issue 12, 2014, Pages 1-3

  Štulc, Tomáš ^a   Češka, Richard ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cardiovascular risk; Diabetes mellitus; Diabetogenic; Glycemia; Statins

Indexed keywords

HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; GLUCOSE BLOOD LEVEL;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETOGENESIS; DISEASE COURSE; DRUG MECHANISM; DRUG USE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; GLYCEMIC INDEX; HYPERCHOLESTEROLEMIA; MALE; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; SENSITIVITY AND SPECIFICITY;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; GLYCEMIC INDEX; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; NEEDS ASSESSMENT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84949133304     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0458-5     Document Type: Review

References (17)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
2. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
3. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014;15:1–15.
4. Maki KC, Ridker PM, Brown WV, Grundy SM, Sattar N. An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol. 2014;8:S17–29.
5. FDA. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 2012. http://www.fda.gov/drugs/drugsafety/ucm293101.htm. Accessed 4 September 2014
6. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.
7. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med. 2011;171:404–10.
8. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95.
9. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209–16.
10. Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009;57:495–9.
11. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart protection study collaborative group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–16.
12. Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA. Atorvastatin in factorial with omega 3 EE90 risk reduction in diabetes study group. atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia. 2009;52:50–9.
13. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223:197–203.
14. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.
15. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–31.
16. Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010;7:e1000278.
17. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–8.